All In Biotech

Drug Trial Radar · NCT06427941

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

A Phase 1/2 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

630

Planned (sponsor's estimate)

Start

Jul 23, 2024

Primary completion

Mar 31, 2027

Study completion Oct 31, 2028

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
May 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of BGB-B2033 alone or in combination with tislelizumab, with or without bevacizumab, in adults with advanced or metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-producing gastric cancer (GC), extragonadal yolk sac tumors, non-dysgerminomas, or glypican-3 (GPC3)-positive squamous non-small cell lung cancer (NSCLC). The study will also determine the recommended Phase 2 dose (RP2D) of BGB-B2033 when given alone or in combination with tislelizumab and bevacizumab. The main questions it aims to answer are: * Is BGB-B2033 safe and tolerable when given alone or in combination with tislelizumab, with or without bevacizumab? * How does the body process BGB-B2033, and what are its effects on the body? * Does BGB-B2033 show preliminary antitumor activity in participants with advanced or metastatic cancer? Researchers will evaluate different doses and treatment combinations to determine the safest and most appropriate dose of BGB-B2033 for further study. Participants will: * Receive BGB-B2033 by intravenous infusion, either alone or in combination with tislelizumab, with or without bevacizumab. * Have regular assessments to monitor safety, side effects, how their body processes and responds to BGB-B2033, and whether their cancer responds to treatment.

Conditions

  • Metastatic Hepatocellular Carcinoma
  • Local Advanced Hepatocellular Carcinoma
  • Alpha-fetoprotein (AFP)-Producing Gastric Cancer
  • Extragonadal Yolk Sac Tumors
  • Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer

Interventions

  • BGB-B2033Drug

    Administered by intravenous infusion

  • TislelizumabDrug

    Administered by intravenous infusion

  • BevacizumabDrug

    Administered by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A and B: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to approximately 2 years
  2. Part A and B: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-B2033Time frame: Up to approximately 2 years
  3. Part A and B: Recommended Phase 2 dose (RP2D) of BGB-B2033Time frame: Up to approximately 2 years
  4. Parts C, D, and E: Overall Response Rate (ORR) as assessed by the Independent Review Committee (IRC)Time frame: Up to approximately 2 years

Locations

51 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Alabama At Birmingham Hospital

    Birmingham, Alabama · Recruiting

  • City of Hope Phoenix Cancer Center

    Goodyear, Arizona · Recruiting

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • City of Hope Chicago Cancer Center

    Zion, Illinois · Recruiting

  • Memorial Sloan Kettering Cancer Center Mskcc

    New York, New York · Recruiting

  • Upmc Hillman Cancer Center(Univ of Pittsburgh)

    Pittsburgh, Pennsylvania · Recruiting

  • Scri Oncology Partners

    Nashville, Tennessee · Recruiting

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas · Recruiting

  • Fundacao Pio Xii Hospital de Amor de Barretos

    Barretos, Brazil · Recruiting

  • Centro Gaucho Integrado de Oncologia Hospital Mae de Deus

    Porto Alegre, Brazil · Recruiting

  • Hospital Da Bahia

    Salvador, Brazil · Recruiting

  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto

    São José do Rio Preto, Brazil · Recruiting

  • Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira

    São Paulo, Brazil · Recruiting

  • Anhui Provincial Hospital

    Hefei, Anhui, China · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Mengchao Hepatobiliary Hospital of Fujian Medical University

    Fuzhou, Fujian, China · Recruiting

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Nanfang Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Guangxi Medical University Cancer Hospital Wuxiang Branch

    Nanning, Guangxi, China · Recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Recruiting

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • The Second Affiliated Hospital of Nanchang Universityhongjiaozhou Branch

    Nanchang, Jiangxi, China · Recruiting

  • Sichuan Cancer Hospital and Institute

    Chengdu, Sichuan, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

  • Lishui Central Hospital

    Lishui, Zhejiang, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

  • Hopital Beaujon

    Clichy, France · Recruiting

  • Centre Hospitalier Universitaire Nantes Hotel Dieu

    Nantes, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • Irccs Istituto Nazionale Tumori Fondazione Pascale

    Naples, Italy · Recruiting

  • Iov Istituto Oncologico Veneto Irccs

    Padova, Italy · Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli

    Roma, Italy · Recruiting

  • Irccs Humanitas Research Hospital

    Rozzano, Italy · Recruiting

  • Kindai University Hospital

    Sakai, Osaka, Japan · Recruiting

  • Tokyo Metropolitan Komagome Hospital

    Bunkyoku, Tokyo, Japan · Recruiting

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.